Lazard Asset Management
TVTX icon

Lazard Asset Management’s Travere Therapeutics TVTX Stock Holding History

Lazard Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$316K Buy
+5,555
New +$246K ﹤0.01% 1552
2026
Q1 		– Sell
-9,984
Closed -$381K – 2086
2025
Q4 		$381K Buy
+9,984
New +$325K ﹤0.01% 1460
2025
Q3 		– Sell
-5,461
Closed -$80K – 2324
2025
Q2 		$80K Sell
5,461
-4,457
-45% -$73.9K ﹤0.01% 1913
2025
Q1 		$177K Buy
9,918
+4,201
+73% +$85.3K ﹤0.01% 1656
2024
Q4 		$99K Buy
+5,717
New +$101K ﹤0.01% 1800
2023
Q4 		– Sell
-11,862
Closed -$106K – 2474
2023
Q3 		$106K Sell
11,862
-45,038
-79% -$636K ﹤0.01% 1612
2023
Q2 		$873K Sell
56,900
-44,515
-44% -$810K ﹤0.01% 1017
2023
Q1 		$2.28M Sell
101,415
-24,174
-19% -$514K ﹤0.01% 894
2022
Q4 		$2.64M Buy
+125,589
New +$2.66M ﹤0.01% 857
2022
Q3 		– Sell
-703
Closed -$17K – 2561
2022
Q2 		$17K Sell
703
-51
-7% -$1.28K ﹤0.01% 2153
2022
Q1 		$19K Sell
754
-4,299
-85% -$114K ﹤0.01% 2081
2021
Q4 		$156K Buy
5,053
+578
+13% +$16.3K ﹤0.01% 1328
2021
Q3 		$108K Buy
+4,475
New +$82.2K ﹤0.01% 1401
2021
Q1 		– Sell
-3,616
Closed -$98K – 2028
2020
Q4 		$98K Hold
3,616
– – ﹤0.01% 1189
2020
Q3 		$66K Sell
3,616
-1,970
-35% -$38.3K ﹤0.01% 1106
2020
Q2 		$114K Buy
5,586
+1,267
+29% +$20.2K ﹤0.01% 992
2020
Q1 		$63K Buy
+4,319
New +$65K ﹤0.01% 1111
2019
Q4 		– Sell
-875
Closed -$10K – 1669
2019
Q3 		$10K Buy
+875
New +$14.5K ﹤0.01% 1309

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lazard Asset Management's TVTX Position: Q2 2026 in Review

Lazard Asset Management opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 5,555 shares worth $316K. The stake represents ﹤0.01% of the portfolio and ranks #1552 among its holdings. This is a return to the name: Lazard Asset Management previously reported a position in TVTX as recently as Q4 2025.

Lazard Asset Management first reported a position in TVTX in Q3 2019 and has held it in 18 quarters since. The position peaked at $2.64M in Q4 2022. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Lazard Asset Management held 5,555 shares of Travere Therapeutics worth $316K as of Q2 2026.
  • Travere Therapeutics was a new Lazard Asset Management position in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1552 holding.
  • Lazard Asset Management first reported a position in Travere Therapeutics in Q3 2019 and has held it in 18 quarters since.
  • Lazard Asset Management's Travere Therapeutics position peaked at $2.64M in Q4 2022.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.